Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL-7010 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion |
| Cohort B | EXPERIMENTAL | Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion |
| Cohort C | EXPERIMENTAL | Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion |
| Cohort D | EXPERIMENTAL | Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion |
| Cohort E | EXPERIMENTAL | Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion |
| Name | Type | Description |
|---|---|---|
| BL-7010 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Males or females aged 18-75 years who have signed an informed consent form * Body mass index (BMI) between 18.5-29.9, inclusive * Documented history of biopsy-proven celiac disease. * Adherence to a gluten-free diet for the last 6 months prior to randomization * TG2 and EMA an...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | Amlitelimab |
| Forte Biosciences Inc. | FBRX | 1 | PHASE2 | FB102 |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 1 | PHASE2 | TEV-53408 |
| Barinthus Biotherapeutics plc Sponsored ADR | BRNS | 1 | EARLY_PHASE1 | VTP-1000 |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
BL-7010 is an investigational small molecule being developed for the treatment of celiac disease, a gastrointestinal condition. It is designed to address the needs of patients with this autoimmune disorder, though it is not yet approved and remains in clinical development.
BL-7010 is being developed by BioLineRx Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BLRX. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy for celiac disease.
BL-7010 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is not currently in active clinical trials.
BL-7010 has one completed Phase 1 clinical trial, identified as NCT01990885. This study, titled 'Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients,' was conducted in Finland with 40 participants and evaluated the drug's safety and systemic exposure.
Yes, the Phase 1 clinical trial for BL-7010 (NCT01990885) was a randomized, double-blind, controlled study. It enrolled 40 adults aged 18 years and older with celiac disease, and the trial has been completed.